ALKBH5 and neoplasm: Similarly, ALKBH5 inhibitors—such as MV1035 analogs—have been shown to reduce PD-L1 expression and rescue anti-tumor immunity in glioblastoma allografts, highlighting the potential of “eraser” blockade to overcome immune escape (5, 16).